Cancer Family
Neuroepithelial, Perineurial, and Schwann Cell Neoplasm
CI-CAN-00000039Explore in graph →
Non-malignant864 active trials6 approved drugs159 evidence items
- NCIt
- C35562
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000039Explore in graph →
Clinical trials
3,131 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06470711 | Mapping of Electrical Properties in the Brain | recruiting | — | 120 | Mayo ClinicOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT02394626 | Surgery for Recurrent Glioblastoma(RESURGE) | recruiting | Phase 2 | 120 | Insel Gruppe AG, University Hospital BernOTHER | 9 | Feb 2, 2026 | clinicaltrials |
| NCT05464992 |
| Use of CEST (Chemical Exchange Saturation Transfer) Imaging in PET/MRI(GlioCEST) |
| recruiting |
| N/A |
| 800 |
| Centre Paul StraussOTHER |
| 1 |
| Feb 2, 2026 |
| clinicaltrials |
| NCT05683808 | Venous Thromboembolism Prevention in Outpatients With Glioma(VTE-POG) | recruiting | Phase 2 | 40 | University of Vermont Medical CenterOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT04702581 | A Randomized Trial of Delayed Radiotherapy in Patients Low-grade Oligodendrogliomas Requiring a Treatment Other Than Surgery(POLO) | recruiting | Phase 3 | 280 | Hospices Civils de LyonOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT05762419 | FUS Etoposide for DMG | recruiting | Phase 1 | 10 | Columbia UniversityOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT04865315 | A Living Tissue Bank of Patient-Derived Organoids From Glioma Tumors(HiLoGlio) | recruiting | — | 50 | Maastricht Radiation OncologyOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT04196413 | GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG) | recruiting | Phase 1 | 97 | Stanford UniversityOTHER | 1 | Jan 26, 2026 | clinicaltrials |
| NCT07364786 | Effect of Salovum® on Pressure, Oxygen and Inflammation in Glioblastoma(AFGBMBiop) | recruiting | Phase 2 | 10 | Peter SiesjöOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07364955 | Vestibular Rehabilitation Protocol in Unilateral Vestibular Schwannoma | recruiting | N/A | 75 | Albert Torrents TorreroOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT05084430 | Study of Pembrolizumab and M032 (NSC 733972) | recruiting | Phase 1 / Phase 2 | 28 | University of Alabama at BirminghamOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT07143812 | A Study to Evaluate the Safety of a Stem Cell-Based Gene and Cell Therapy in Patients With Newly Diagnosed Glioblastoma | recruiting | Phase 1 | 10 | CHA UniversityOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT06630260 | 5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours(5G-RUBY) | recruiting | Phase 1 / Phase 2 | 182 | Institute of Cancer Research, United KingdomOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT06625684 | Key Longitudinal Associations With Risk and Glioblastoma Outcomes(Key LARGO) | recruiting | — | 200 | Duke UniversityOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT03144167 | Study of Prognostic Biomarkers of Survival at 6 Months for Patients Treated With Bevacizumab Glioblastomas in First Relapse After Failure of Radiochemotherapy(SPECTROBEVA) | recruiting | N/A | 170 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT05465954 | Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma | recruiting | Phase 2 | 54 | Mayo ClinicOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT05083754 | Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma | recruiting | Phase 1 | 50 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT05106296 | Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer | recruiting | Phase 1 | 37 | Theodore S. JohnsonOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT05669820 | Antisecretory Factor Glioblastoma Phase 2(AFGB2) | recruiting | Phase 2 / Phase 3 | 300 | Peter SiesjöOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT07240662 | Vorasidenib in CNS WHO Grade 2 IDH-mutant Diffuse Glioma(VIOLETA) | recruiting | — | 150 | iOMEDICO AGINDUSTRY | 1 | Jan 9, 2026 | clinicaltrials |
| NCT06849986 | IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)(TAIS) | recruiting | Phase 2 | 45 | Fudan UniversityOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT02358187 | A Vaccine Trial for Low Grade Gliomas | recruiting | Phase 2 | 25 | James FelkerOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT03267459 | Can Pretreatment MRI be Used to Predict Intra-arterial Chemotherapy Response in Retinoblastoma?(PREDIR) | recruiting | — | 60 | Fondation Ophtalmologique Adolphe de RothschildNETWORK | 1 | Jan 5, 2026 | clinicaltrials |
| NCT05049148 | Platelets Activation in Brain Neoplasms(Platon) | recruiting | N/A | 50 | Fondation Ophtalmologique Adolphe de RothschildNETWORK | 1 | Jan 5, 2026 | clinicaltrials |
| NCT06717295 | The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling(CCANED-CIPHER) | recruiting | — | 6,000 | Javier ToledoINDUSTRY | 3 | Jan 2, 2026 | clinicaltrials |
| NCT06829173 | Concurrent XRD-0394 With Radiation Therapy for High Grade Gliomas | recruiting | Early Phase 1 | 39 | NYU Langone HealthOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT07093814 | A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma | recruiting | Phase 1 / Phase 2 | 42 | Guangzhou Virotech Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 2, 2026 | clinicaltrials |
| NCT06645808 | PET-imaging of Two Vartumabs in Patients With Solid Tumors(VARTUTRACE) | recruiting | Early Phase 1 | 32 | Var2 PharmaceuticalsINDUSTRY | 1 | Dec 29, 2025 | clinicaltrials |
| NCT07306299 | A Phase I Clinical Trial of a mRNA Vaccine for Recurrent or Progressive High-grade Glioma | recruiting | Phase 1 | 10 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Dec 29, 2025 | clinicaltrials |
| NCT05423210 | Atezolizumab and Pre-Surgical Brain Radiation Therapy for Glioblastoma Multiforme | recruiting | Early Phase 1 | 12 | Stony Brook UniversityOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT06468176 | Efficacy of a Mixed Distancial Neuropsychological Rehabilitation Program in Patients With Grade 2 or 3 Diffuse Glioma(FREEDOME) | recruiting | N/A | 187 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT07145047 | Clinical Study of Oncolytic Virus in Glioblastoma | recruiting | Phase 1 / Phase 2 | 20 | Mianyang Central HospitalOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT04541082 | Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms | recruiting | Phase 1 | 102 | Jazz PharmaceuticalsINDUSTRY | 1 | Dec 18, 2025 | clinicaltrials |
| NCT04543201 | Telehealth Visits to Discuss Advanced Directives for Patients Newly Diagnosed With High Grade Glioma | recruiting | N/A | 50 | University of RochesterOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT05259605 | Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification | recruiting | — | 1,650 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 12 | Dec 17, 2025 | clinicaltrials |
| NCT05976490 | NeuroPathways Intervention for Brain Tumor Patients | recruiting | N/A | 50 | Massachusetts General HospitalOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT05686798 | Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma. | recruiting | Phase 1 | 18 | Henry Ford Health SystemOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT07286903 | Fluorescence Enhanced Stereotactic Surgery (FESS)(FESS) | recruiting | — | 20 | Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT07286929 | Evaluation of the Variation Over Time of Visuospatial Deficit in Patients With Parietal Lobe Glioma(neGLIO) | recruiting | — | 40 | Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT05956821 | Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age | recruiting | Phase 1 / Phase 2 | 20 | University of MiamiOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT07077616 | Clinical Study for the Safety and Therapeutic Efficacy of the AI-QMMM Designed TamavaqTM Personalised Vaccine in Patients With Newly Diagnosed Glioma.(TAMAVAQTM) | recruiting | Early Phase 1 | 29 | Biogenea Pharmaceuticals Ltd.INDUSTRY | 1 | Dec 8, 2025 | clinicaltrials |
| NCT05553041 | 18F-Fluciclovine PET-MRI in High-grade Glioma | recruiting | Early Phase 1 | 30 | Children's Hospital of PhiladelphiaOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT06961565 | PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas | recruiting | Phase 1 | 56 | Pasithea Therapeutics Corp.INDUSTRY | 3 | Dec 4, 2025 | clinicaltrials |
| NCT07263711 | Prospective Real-World Study of Pathology AI for Glioma Molecular Prediction | recruiting | — | 2,000 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT05990244 | Magnetic Resonance Elastography in Glioma: Exploring Tumor Stiffness and Adhesion | recruiting | N/A | 100 | Shengjing HospitalOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT06964815 | Silibinin in Association With Concomitant Chemoradiotherapy and Maintenance Temozolomide in STAT3 Positive IDH Wild-type, Newly Diagnosed Glioblastoma Patients(STRONG) | recruiting | N/A | 110 | Istituto Oncologico Veneto IRCCSOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT04681417 | Ocular Conservative Treatment for Retinoblastoma : Efficacy of the New Management Strategies and Visual Outcome(RETINO 2018) | recruiting | Phase 2 / Phase 3 | 225 | Institut CurieOTHER | 1 | Nov 28, 2025 | clinicaltrials |
| NCT05768178 | DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT05770544 | DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT06988475 | DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Feb 3, 2026source: clinicaltrials